AstraZeneca Shares Dive After Major Setback Over Cancer Drugs

AstraZeneca said a combination of two of its new oncology drugs failed to shrink lung cancer tumors in a clinical trial, casting doubt on a central part of its ambitious growth plans. Shares fell 16%.

Popular Posts


EOF

(Visited 1 times, 1 visits today)

Vote on this story -->>>


this is a single

THE MIAMI METROPOLIS -your source for news, music, sports, movies, restaurants, reviews, weather, travel, arts, tech and events in Miami